Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was established in 2006, with a history that can be traced back to Protagonist Pty Limited (Protagonist Australia, currently a subsidiary of PTGX) founded in Australia in September 2001, headquartered in Milpitas, California, USA, with 62 full-time employees Ren, is a clinical-stage biopharmaceutical company with a proprietary technology platform that focuses on the discovery and development of peptide-based new chemical entities (New Chemical Entities, NCEs) to address significant unmet medical needs.
Protagonist Therapeutics (PTGX):
Protagonist Therapeutics is also mainly developing oral peptide biologics that have been approved by the US FDA and clinically validated injectable antibody drugs. The company believes that this can greatly reduce the risk of R&D failure and can also have a differentiated competitive advantage: Compared with injections Antibody-like drugs, Protagonist Therapeutics’ oral peptide formulations can be targeted for delivery, so it can improve safety. In addition, because it is oral, it is cheaper and more convenient, especially for some gastrointestinal diseases.
Protagonist Therapeutics (PTGX) product candidates:
Protagonist Therapeutics (PTGX) investment:
Protagonist Therapeutics, Inc. submitted its IPO prospectus on July 11, 2016. The IPO landed on Nasdaq on August 11, 2016. The issue price was US$12.00. It issued 5,835,000 shares and raised US$87,233,250. The stock code: PTGX.